Market closed

Viking Therapeutics/$VKTX

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Viking Therapeutics

Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

Ticker

$VKTX
Trading on

Industry

Biotechnology

Employees

31

VKTX Metrics

BasicAdvanced
$5.8B
Market cap
-
P/E ratio
-$0.93
EPS
1.00
Beta
-
Dividend rate
$5.8B
1
$99.41
$11.21
5.5M
36.467
36.225
0.083
0.135
-1,395.50%
-12.68%
-15.50%
6.31
6.31
-73.836
2.22%
9.77%

What the Analysts think about VKTX

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Viking Therapeutics stock.

VKTX Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

VKTX Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $VKTX

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Viking Therapeutics stock?

Viking Therapeutics (VKTX) has a market cap of $5.8B as of November 23, 2024.

What is the P/E ratio for Viking Therapeutics stock?

The price to earnings (P/E) ratio for Viking Therapeutics (VKTX) stock is 0 as of November 23, 2024.

Does Viking Therapeutics stock pay dividends?

No, Viking Therapeutics (VKTX) stock does not pay dividends to its shareholders as of November 23, 2024.

When is the next Viking Therapeutics dividend payment date?

Viking Therapeutics (VKTX) stock does not pay dividends to its shareholders.

What is the beta indicator for Viking Therapeutics?

Viking Therapeutics (VKTX) has a beta rating of 1. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.